Skip to content
value.today
Mirum Pharmaceuticals, Inc. logo

Mirum Pharmaceuticals, Inc.

Total raised
$60 M
1 round on record
Latest round
$60 M
Nov 2018
First round on record
Nov 2018
Today
Went public
See the company page

Mirum Pharmaceuticals, Inc. is listed today as Mirum Pharmaceuticals, Inc.: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding, 2 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Mirum Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2026$68 MPrivate placement after listing$50 to $250 million

Mirum Pharmaceuticals, Inc.: Private sale, Jan 2026

Investors in this round

2 investors had bought by the notice of Jan 29, 2026: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 12 investors are named for Mirum Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$68 M of $68 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(c): may be advertised publicly; every buyer must be a verified accredited investor
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christopher Peetz · Executive Officer, Director
  • Eric Bjerkholt · Executive Officer
  • Peter Radovich · Executive Officer
  • Laura Brege · Director
  • Laurent C. Fischer · Director
  • Lon C. Cardon · Director
  • Michael C. Grey · Director
  • Patrick C. Heron · Director
  • Saira C. Ramasastry · Director
  • Timothy Walbert · Director
  • William C. Fairey · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Eric Bjerkholt, Chief Financial Officer. Source: SEC Form D, newest notice filed Jan 29, 2026. Read the notice at the SEC.

equitySEC
Dec 2020$10 MPrivate placement after listing$10 to $50 million

Mirum Pharmaceuticals, Inc.: Private sale, Dec 2020

Investors in this round

3 investors had bought by the notice of Dec 30, 2020: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 12 investors are named for Mirum Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christopher J. Peetz · Executive Officer, Director
  • Edwin Jonathan Tucker · Executive Officer
  • Ian J. Clements · Executive Officer
  • Lara J. Longpre · Executive Officer
  • Pamela Jonathan Vig · Executive Officer
  • Peter J. Radovich · Executive Officer
  • Edward T. Mathers · Director
  • Laura J. Brege · Director
  • Laurent J. Fischer · Director
  • Michael G. Grey · Director
  • Niall J. O'Donnell · Director
  • Patrick J. Heron · Director
  • Tiba J. Aynechi · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Ian Clements, Chief Financial Officer. Source: SEC Form D, newest notice filed Dec 30, 2020. Read the notice at the SEC.

equitySEC
Nov 2018$60 MNo. 1$50 to $250 million

Mirum Pharmaceuticals, Inc.: Raise no. 1, Nov 2018

Investors in this round

14 investors had bought by the notice of Nov 20, 2018: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 12 investors are named for Mirum Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$60 M of $120 M offered; $60 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Michael Grey · Executive Officer, Director
  • Susan Dube · Executive Officer
  • Chris Peetz · Director
  • Ed Mathers · Director
  • Jonathan Leff · Director
  • Patrick Heron · Director
  • Tiba Aynechi · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Includes amounts paid both in cash and pursuant to automatic conversion of indebtedness.”

Signed by Susan Dube, Chief Financial Officer. Source: SEC Form D, newest notice filed Nov 20, 2018. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Mirum Pharmaceuticals, Inc., its revenue in fiscal 2025 came from these product and service lines: Livmarli $360.01 million (69%), Bile Acid Medicines $161.31 million (31%).

    Annual report (SEC XBRL) · Dec 2025

  • Mirum Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2026).

    SEC Form D · Jan 2026

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jan 2026

Products and services#

No products or services of Mirum Pharmaceuticals, Inc. are on record.

Investors#

12 named in official filings. Open an investor to see everything it has backed.

Investors in Mirum Pharmaceuticals, Inc.
InvestorKindAmountRoundRoleSource
Deerfield Healthcare Innovations Fund, L.P.Fund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Deerfield Management Company, L.P.Fund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Deerfield Mgmt HIF, L.PFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Deerfield Mgmt IV, L.P.Fund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Deerfield Private Design Fund IV, L.P.Fund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Fhmls IX, L.L.C.Othernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Fhmls IX, L.P.Fund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Frazier Life Sciences IX, L.P.Fund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Nea 16 GP, LLCOthernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2019)SEC Form 3
NEA Partners 16, L.P.Fund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2019)SEC Form 3
New Enterprise Associates 16, L.P.Fund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Novo Holdings A/sFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2019)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 14 investors.

Largest shareholders today

Institutions holding Mirum Pharmaceuticals, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Mirum Pharmaceuticals, Inc.
NameRoleNamed in
Christopher PeetzExecutive officerJan 2026
Eric BjerkholtExecutive officerJan 2026
Peter RadovichExecutive officerJan 2026
Christopher J. PeetzExecutive officerDec 2020
Edwin Jonathan TuckerExecutive officerDec 2020
Ian J. ClementsExecutive officerDec 2020
Lara J. LongpreExecutive officerDec 2020
Pamela Jonathan VigExecutive officerDec 2020
Peter J. RadovichExecutive officerDec 2020
Michael GreyExecutive officerNov 2018
Susan DubeExecutive officerNov 2018
Christopher PeetzDirectorJan 2026
Laura BregeDirectorJan 2026
Laurent C. FischerDirectorJan 2026
Lon C. CardonDirectorJan 2026
Michael C. GreyDirectorJan 2026
Patrick C. HeronDirectorJan 2026
Saira C. RamasastryDirectorJan 2026
Timothy WalbertDirectorJan 2026
William C. FaireyDirectorJan 2026
Christopher J. PeetzDirectorDec 2020
Edward T. MathersDirectorDec 2020
Laura J. BregeDirectorDec 2020
Laurent J. FischerDirectorDec 2020
Michael G. GreyDirectorDec 2020
Niall J. O'DonnellDirectorDec 2020
Patrick J. HeronDirectorDec 2020
Tiba J. AynechiDirectorDec 2020
Chris PeetzDirectorNov 2018
Ed MathersDirectorNov 2018
Jonathan LeffDirectorNov 2018
Michael GreyDirectorNov 2018
Patrick HeronDirectorNov 2018
Tiba AynechiDirectorNov 2018

About

Biopharmaceutical company.

Went public since 2019. Its SEC number is that of a company listed on a stock exchange.